Browse the evidence

Tirzepatide can cause rare, idiosyncratic hepatocellular injury presenting as asymptomatic or symptomatic aminotransferase elevation, which resolves upon drug discontinuation.

If you are taking tirzepatide and develop persistent abdominal pain, nausea, or dark urine, do not assume it is just a standard side effect. Request liver enzyme testing (ALT/AST) immediately. If elevated, stopping the medication typically resolves the injury, but early detection prevents severe liver damage.

Tirzepatide use is associated with a high frequency of early-onset adverse events, with a median time-to-onset of approximately 6.4 days, driven by gastrointestinal disturbances, injection site reactions, and metabolic effects.

If you start tirzepatide, expect side effects like nausea or injection site pain to happen quickly, often within the first week. This is common and usually transient, but you should monitor yourself closely during the initial days of treatment.

Tirzepatide use is associated with specific adverse events in females, including starvation ketoacidosis, menstrual disorders, and postmenopausal hemorrhage.

Women taking tirzepatide should be aware of potential changes in their menstrual cycle, including irregular bleeding or postmenopausal hemorrhage. If you experience these changes, consult your healthcare provider.

Tirzepatide use is associated with specific adverse events in males, including sleep disorders, delayed gastric emptying, and medullary thyroid cancer.

Men taking tirzepatide should be aware of potential sleep issues and digestive delays. Those with a family history of thyroid cancer should discuss the risks with their doctor before starting treatment.

Off-label use of GLP-1 receptor agonists (specifically semaglutide) for weight loss can precipitate euglycemic starvation ketoacidosis in non-diabetic individuals, primarily through gastrointestinal side effects causing reduced oral intake and starvation.

If you are using GLP-1 medications like semaglutide for weight loss, do not source them from unregulated online pharmacies. The risk of receiving counterfeit or improperly dosed products is real and can lead to severe metabolic issues. If you experience persistent nausea, vomiting, or inability to eat, seek medical attention immediately, as this can lead to euglycemic ketoacidosis—a dangerous condition where your blood becomes acidic despite normal blood sugar levels. Never ignore severe gastrointestinal side effects.

Post-market surveillance is investigating potential links between GLP-1 receptor agonists and suicidal ideation, as well as an increased risk of thyroid cancer of all histologic subtypes.

Stay informed about post-market surveillance findings. The FDA has issued warnings regarding suicidal behavior, and studies suggest a higher risk of thyroid cancer. Discuss these risks with your healthcare provider and follow current evidence-based counseling.

Dietary supplementation with Docosahexaenoic acid (DHA) attenuates nonalcoholic steatohepatitis (NASH) and fibrosis by suppressing Betacellulin (BTC) expression, thereby inhibiting the BTC-EGFR-ERBB pathway, reducing hepatic stellate cell proliferation, and lowering TGFβ-2-mediated collagen production.

If you are managing NASH or liver health, the specific type of Omega-3 matters. Research indicates DHA is more effective than EPA at suppressing key liver damage pathways (like Betacellulin and TGFβ-2). While this study is in mice, it suggests prioritizing DHA-rich sources or supplements over generic Omega-3 blends for liver-specific benefits.

GLP-1 receptor agonists (GLP1RAs) do not increase the risk of adverse events compared to other anti-obesity medications in patients who have undergone bariatric surgery.

If you have had bariatric surgery and are considering GLP-1 medications (like Semaglutide or Liraglutide) for weight regain, current data indicates they are not more dangerous than other standard weight loss drugs. The risk of serious complications is low and similar to other options. However, starting these medications more than 12 months after surgery appears to have a lower risk of adverse events than starting them earlier.

Systemic administration of the GIP receptor agonist DA-GIP suppresses inflammation-induced conditioned taste avoidance (CTA) and reduces parabrachial CGRP neuron activation, acting via distinct neural circuits than its anorectic effects.

For individuals experiencing severe nausea or food aversion due to inflammation (e.g., chronic autoimmune conditions or post-infection), standard anti-nausea medications (like ondansetron) or anti-inflammatories (NSAIDs) may not fully resolve the aversion. Emerging GIP-based therapies show promise in specifically targeting the neural circuits responsible for this aversion without necessarily worsening appetite suppression, potentially improving quality of life during inflammatory episodes.

GIP receptor agonism enhances inflammation-induced anorexia via the Dorsal Vagal Complex (DVC), while its anti-aversive effects are mediated by parabrachial CGRP neurons, demonstrating that food intake suppression and aversion are dissociable.

Current understanding of GLP-1/GIP drugs often focuses on weight loss. This research suggests these drugs also have a distinct, potent anti-nausea/anti-aversion effect mediated by different brain circuits. This dual-action profile could be leveraged to manage quality of life in patients with chronic inflammatory conditions who suffer from both weight loss and severe food aversion.

Low-dose semaglutide (30 nmol/kg twice weekly) attenuates pathological cardiac and hepatic remodeling and improves exercise capacity in a rodent model of HFpEF independently of weight loss.

This preclinical study suggests that low-dose GLP-1 therapy may offer direct heart and liver protection in heart failure with preserved ejection fraction (HFpEF) without requiring weight loss. While promising, this is animal data; human application requires clinical validation.

Tirzepatide demonstrates greater clinical potency than semaglutide, potentially due to glucose-dependent insulinotropic polypeptide (GIP) receptor activation increasing energy expenditure.

If you are struggling with weight loss on a GLP-1 drug like semaglutide, ask your doctor about tirzepatide. It targets two hormones (GIP and GLP-1) instead of just one, which may lead to greater weight loss for some people by increasing how much energy you burn.

In patients with Type 2 Diabetes and Heart Failure with reduced ejection fraction (HFrEF), treatment with GLP-1 receptor agonists significantly reduces all-cause mortality and major cardiovascular events compared to DPP-4 inhibitors.

If you have Type 2 Diabetes and reduced heart function (HFrEF), GLP-1 medications (like semaglutide or dulaglutide) are associated with a significantly lower risk of death and heart-related hospitalizations compared to DPP-4 inhibitors. This benefit appears early and persists over 5 years, regardless of age or sex. Discuss these options with your cardiologist, as they may offer cardiovascular protection beyond blood sugar control.

A single meal containing 72g of digestible carbohydrates inhibits ketosis (lipolysis) for several days, with recovery time dependent on baseline fasting insulin levels.

If you are relying on ketosis for fat loss, avoid high-carb meals entirely. A single meal with ~72g of carbs (e.g., bread and jam) can stop fat burning for 2 to 5 days, or indefinitely if your fasting insulin is high. Recovery time depends on your metabolic health; those with higher insulin levels may never recover ketosis within a standard 2-week window.

Bypassing or modifying the small intestine (via surgery or endoscopy) induces type 2 diabetes remission and improves glycemic control, independent of weight loss alone.

If you have obesity and Type 2 Diabetes, standard weight loss might not be enough. Modern endoscopic procedures that target the small intestine (like bypass liners or mucosal resurfacing) can induce diabetes remission and improve blood sugar control, often with less risk than traditional surgery. However, these are complex treatments requiring a multidisciplinary team to select the right procedure for your specific body type and ethnicity.

Medicare-aged adults (65-69) with obesity but without Type 2 Diabetes have significantly lower prescribing and dispensing rates of anti-obesity GLP-1 receptor agonists compared to adults aged 60-64, likely due to Medicare's prohibition on covering these medications.

If you are over 65 and have obesity but no diabetes, you may face significant barriers to accessing GLP-1 medications like Wegovy or Zepbound because Medicare currently prohibits coverage for these specific anti-obesity drugs. This results in significantly lower prescribing and filling rates compared to those aged 60-64. Consult your provider about available options, but be aware that cost and coverage restrictions may limit your access to these specific hormonal treatments.

Patients who use anti-obesity medications (AOMs) prior to surgery experience significant weight regain (average 18 kg) upon discontinuation, yet this experience does not change their expectation of weight loss from surgery.

If you stop taking weight loss drugs, you will likely regain most of the weight you lost (average 18kg). This is common. However, this experience does not mean you are destined to fail surgery. Many patients use surgery to achieve greater weight loss than drugs alone, and some even use drugs after surgery to enhance results.

Administration of the chimeric multi-agonist peptide GEP44 reduces body weight and energy intake in diet-induced obese mice primarily through a GLP-1 receptor (GLP-1R) dependent mechanism.

This research indicates that a new peptide drug called GEP44 can help reduce body weight and food intake in obese mice by targeting specific receptors in the brain. The effects rely heavily on the GLP-1 receptor, similar to drugs like Ozempic or Wegovy, but GEP44 also targets other receptors (Y1 and Y2). While promising in mice, this is preprint research and not yet available for human use.

Roux-en-Y gastric bypass (RYGB) surgery increases glycemic variability and time in hypoglycemic ranges in both diabetic and non-diabetic patients within six months post-operation, with non-diabetic patients showing a significant decrease in time in range due to increased hypoglycemia.

If you undergo Roux-en-Y gastric bypass, expect your blood sugar to fluctuate more, including episodes of low blood sugar (hypoglycemia), even if you did not have diabetes before. This happens because the surgery speeds up how food enters your intestine. Use a continuous glucose monitor to track these changes, as standard HbA1c tests might miss these dangerous lows.

Off-label use of generic medications (e.g., metformin, SGLT2 inhibitors) or compounded GLP-1 agonists carries risks of unknown efficacy, safety issues, and potential adverse events compared to FDA-approved anti-obesity medications.

Avoid compounded or off-label obesity medications. They are not regulated for safety or efficacy and may contain unapproved ingredients. Talk to your doctor about FDA-approved options, even if they are expensive, as they are the only ones proven safe and effective.

Use of GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide, dulaglutide) for weight loss is associated with an emerging adverse effect of alopecia, primarily presenting as telogen effluvium or androgenetic alopecia.

If you are using a GLP-1 medication for weight loss and notice increased hair shedding, do not immediately stop the medication. This is a reported side effect, often presenting as temporary shedding (telogen effluvium) linked to metabolic stress or rapid weight loss. Consult a dermatologist to confirm the type of hair loss; it may be manageable without discontinuing your weight loss treatment.

Obesity is a disease of the ponderostat characterized by a dysregulated neuroendocrine set point that actively defends a higher body weight through compensatory reductions in energy expenditure and increases in appetite.

Recognize that obesity involves a biological set point that resists change. Simple calorie counting often fails because the body compensates by lowering metabolism and increasing hunger. Effective management may require addressing these biological drivers, potentially through pharmacological treatments that target the ponderostat, rather than relying solely on willpower.

Use of GLP-1 receptor agonists (GLP-1RAs) is associated with a significantly increased risk of developing alopecia, specifically androgenetic alopecia (AGA), across multiple agents including semaglutide, tirzepatide, dulaglutide, liraglutide, and exenatide.

If you are using a GLP-1RA (like semaglutide or tirzepatide), be aware that there is a statistically significant, though small, increased risk of hair thinning (androgenetic alopecia). This risk varies by drug; tirzepatide did not show this risk in this study, while semaglutide, dulaglutide, and liraglutide did. The risk is not universal, and it does not appear to affect Alopecia Areata. Discuss this with your provider, especially if you have a family history of hair loss, as the mechanism may be related to metabolic changes or rapid weight loss rather than the drug itself.

Tirzepatide use is associated with a very low absolute risk of acute pancreatitis (<1%), and when cases occur, they are typically mild and confounded by traditional etiologies such as gallstones or alcohol.

If you are taking tirzepatide, be aware that pancreatitis is a known but rare side effect (<1% risk). Most cases are mild and often linked to other factors like gallstones. Report severe abdominal pain to your doctor immediately, but do not let fear of this rare event prevent you from using a medication that effectively manages weight and blood sugar.